- Trials with a EudraCT protocol (127)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
127 result(s) found for: Risk stratification.
Displaying page 1 of 7.
EudraCT Number: 2017-001691-39 | Sponsor Protocol Number: UKM17_0023 | Start Date*: 2019-07-16 | |||||||||||
Sponsor Name:University Hospital Münster | |||||||||||||
Full Title: LBL 2018 - International cooperative treatment protocol for children and adolescents with lymphoblastic lymphoma | |||||||||||||
Medical condition: Lymphoblastic lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Trial now transitioned) DE (Ongoing) DK (Trial now transitioned) IE (Completed) NO (Trial now transitioned) FI (Trial now transitioned) AT (Trial now transitioned) CZ (Trial now transitioned) SE (Trial now transitioned) ES (Ongoing) NL (Ongoing) SK (Trial now transitioned) HU (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001501-24 | Sponsor Protocol Number: IRST100.47 | Start Date*: 2020-04-28 | |||||||||||
Sponsor Name:ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI (IRST) S.R.L. IRCCS | |||||||||||||
Full Title: PROTECT: A randomized study with Hydroxychloroquine versus observational support for prevention or early phase treatment of Coronavirus disease (COVID-19). | |||||||||||||
Medical condition: Group 1: SARS-CoV-2-exposed subjects, as household members/contacts of COVID-19 patients Group 2: Patients with COVID-19 asymptomatic or paucisymptomatic in home situation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-003190-99 | Sponsor Protocol Number: 38RC13.410 | Start Date*: 2015-12-09 |
Sponsor Name:CHU de Grenoble | ||
Full Title: Evaluation of the use of an oral direct anti-Xa anticoagulant, Apixaban in prevention of venous thromboembolic disease in patients treated with IMiDs during myeloma: a pilot study | ||
Medical condition: Multiple myeloma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-004883-37 | Sponsor Protocol Number: NB2015LR | Start Date*: 2021-05-12 | |||||||||||
Sponsor Name:University of Cologne | |||||||||||||
Full Title: Prospective multicenter clinical trial for risk estimation and treatment stratification in low and intermediate risk neuroblastoma patients (NB2015-LR) | |||||||||||||
Medical condition: Neuroblastoma, low or intermediate risk | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-001229-15 | Sponsor Protocol Number: PNIC-Na | Start Date*: 2013-08-14 |
Sponsor Name:Fundación para la Investigación Biomédica del Hospital Universitario Ramón y Cajal | ||
Full Title: The efficacy of oral and intravenous administration of sodium chloride in the prophylaxis of nephropathy induced by iodinated contrasts in outpatients | ||
Medical condition: Patients at high risk of developing an iodinated contrast-induced nephropathy. | ||
Disease: | ||
Population Age: Elderly | Gender: Male, Female | |
Trial protocol: ES (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2005-003018-14 | Sponsor Protocol Number: CLL7 | Start Date*: 2006-03-02 |
Sponsor Name:AKH Vienna | ||
Full Title: Randomized phase III trial comparing early treatment with fludarabine, cyclophosphamide + rituximab versus deferred treatment in untreated Binet stage A patients with high risk of progression CLL 7... | ||
Medical condition: chronic lymphocytic leukaemia (CLL) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) CZ (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2013-003956-18 | Sponsor Protocol Number: PREVENT-JIA | Start Date*: 2014-04-29 | |||||||||||
Sponsor Name:University Medical Center Utrecht | |||||||||||||
Full Title: Prevention of disease flares by risk-adapted stratification of therapy withdrawal in juvenile idiopathic arthritis (JIA) | |||||||||||||
Medical condition: juvenile idiopathic arthritis | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-003837-13 | Sponsor Protocol Number: ROPPET-NAF | Start Date*: 2020-04-20 |
Sponsor Name:Centro Hospitalar e Universitário de Coimbra, E.P.E. | ||
Full Title: Rosuvastatin effect on atherosclerotic plaque metabolism ¿ a subclinical atherosclerosis imaging study with 18F-NaF PET-CT | ||
Medical condition: Atherosclerosis, namely in the aorta, carotid and coronary arteries | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: PT (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2012-000427-41 | Sponsor Protocol Number: CPPFAP-310 | Start Date*: 2014-05-15 |
Sponsor Name:Cancer Prevention Pharmaceuticals, Inc. | ||
Full Title: A Double-Blind, Randomized, Phase III Trial of the Safety and Efficacy of CPP-1X/Sulindac Compared With CPP-1X, Sulindac as Single Agents in Patients with Familial Adenomatous Polyposis (FAP) | ||
Medical condition: Familial Adenomatous Polyposis (FAP) | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) DE (Completed) NL (Completed) ES (Completed) BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2019-004685-18 | Sponsor Protocol Number: PSMA-PROSTAPET | Start Date*: 2020-07-28 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA DI MODENA | |||||||||||||
Full Title: Evaluation of diagnostic accuracy of [68Ga]Ga-PSMA-11 PET/CT in primary staging of Intermediate and High Risk Prostatic Cancer in men newly diagnosed | |||||||||||||
Medical condition: Men with histo-pathological confirmation of PCa with intermediate or high-risk disease according to 2019 Prostate Cancer EAU Guidelines Risk Group Stratification | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-001475-20 | Sponsor Protocol Number: FILOCLL10-PREVENE | Start Date*: 2018-12-21 |
Sponsor Name:FILO | ||
Full Title: Preemptive therapy with Venetoclax for high risk CLL stage A patients, a phase II trial of the FILO PREVENE (PREemptive Venetoclax) trial | ||
Medical condition: Chronic lymphoid leukemia | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2019-001585-15 | Sponsor Protocol Number: 2018-01671 | Start Date*: 2020-01-30 |
Sponsor Name:Centre Hospitalier Universitaire Vaudois | ||
Full Title: PTX3 genetically stratified randomized double-blinded allocation eventdriven clinical trial for antifungal prophylaxis in patients with acute myeloid leukemia | ||
Medical condition: Patients with acute myeloid leukemia (AML) or myelodysplastic syndrome in transformation (MDSit) who receive antifungal profylaxis during their treatment with an intensive chemotherapy regimen, inc... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Trial now transitioned) FR (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2006-003371-13 | Sponsor Protocol Number: IM101084 | Start Date*: 2007-07-17 | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: A Phase 3, Multi-Center, Randomized, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy with Abatacept in Subjects with Active Crohn’s Diseas... | |||||||||||||
Medical condition: Crohn's disease, NOS | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) FR (Completed) NL (Prematurely Ended) GB (Prematurely Ended) BE (Completed) IE (Completed) DK (Prematurely Ended) CZ (Completed) PL (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: Removed from public view |
EudraCT Number: 2021-000199-12 | Sponsor Protocol Number: A011-13 | Start Date*: 2022-07-19 | |||||||||||
Sponsor Name:Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ, USA | |||||||||||||
Full Title: A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Sotatercept When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy in Newly Diagnosed Intermediate- and Hig... | |||||||||||||
Medical condition: Pulmonary Arterial Hypertension (PAH) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Trial now transitioned) SE (Prematurely Ended) DE (Trial now transitioned) FR (Trial now transitioned) DK (Trial now transitioned) ES (Ongoing) AT (Trial now transitioned) NL (Trial now transitioned) IT (Trial now transitioned) CZ (Trial now transitioned) PL (Trial now transitioned) PT (Trial now transitioned) HR (Trial now transitioned) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-000478-42 | Sponsor Protocol Number: 008285QM | Start Date*: 2013-02-18 |
Sponsor Name:Queen Mary, University of London | ||
Full Title: NEPTUNE: A Randomised Phase II Study of Neoadjuvant TAK-700 and Leuprorelin Acetate versus Surgery Alone in Intermediate and High Risk Clinically Localized Prostate Cancer | ||
Medical condition: High or Intermediate Risk, Untreated, Clinically Localised Prostate Cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male | |
Trial protocol: GB (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2015-001732-38 | Sponsor Protocol Number: 1502 | Start Date*: 2015-09-14 | |||||||||||
Sponsor Name:CENTRE OSCAR LAMBRET | |||||||||||||
Full Title: EVALUATION OF SENTINEL NODE (SN) POLICY IN EARLY STAGE ENDOMETRIAL CARCINOMAS AT INTERMEDIATE AND HIGH RISK OF RECURRENCE: RANDOMIZED STUDY COMPARING SENTINEL NODE POLICY TO CURRENT FRENCH INITIAL ... | |||||||||||||
Medical condition: Intermediate-risk endometrioïd carcinomas : IAg3, IB(II)g1-2 High-risk endometrioïd carcinomas : IB-II g3 High-risk non endometrioïd carcinomas : I-II | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-001230-18 | Sponsor Protocol Number: PRO-001 | Start Date*: 2019-01-30 | |||||||||||
Sponsor Name:Hellenic Genito-Urinary Cancer Group (HGUCG) | |||||||||||||
Full Title: Long-term thromboprophylaxis with tinzaparin in high-risk prostate or breast cancer patients. A prospective, randomised, international multicentre, open-label, blinded-endpoint Phase III study. PRO... | |||||||||||||
Medical condition: Long-term thromboprophylaxis with tinzaparin in high-risk prostate or breast cancer patients. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GR (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-009421-29 | Sponsor Protocol Number: AAA1 | Start Date*: 2009-05-14 | |||||||||||
Sponsor Name:Cambridge University Hospitals NHS Foundation Trust | |||||||||||||
Full Title: Non - invasive assessment of inflammatory burden in small abdominal aortic aneurysms: A USPIO - enhanced Magnetic Resonance Imaging (MRI) study | |||||||||||||
Medical condition: The thrust of this pilot study is to investigate the utility of USPIO - enhanced MR to image abdominal aortic aneurysms with the aim of highlighting focal areas of inflammation and macrophage infil... | |||||||||||||
|
|||||||||||||
Population Age: | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-002293-39 | Sponsor Protocol Number: BIOIMMUN | Start Date*: 2017-10-10 | |||||||||||
Sponsor Name:ORIOL BESTARD | |||||||||||||
Full Title: MULTICENTER, RANDOMIZED STUDY, TO EVALUATE THE EFFECTIVENESS OF INDIVIDUALIZATION OF IMMUNOLOGICAL RISK BASED ON SELECTIVE BIOMARKERS (DISPARITY OF HLA EPLETS AND ELISPOT-γ) TO OPTIMIZE IMMUNOSUPPR... | |||||||||||||
Medical condition: PROPHYLAXIS OF REJECTION AFTER KIDNEY TRANSPLANTATION | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) NL (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-006523-40 | Sponsor Protocol Number: ML20944 | Start Date*: 2007-04-13 | |||||||||||
Sponsor Name:Roche AB | |||||||||||||
Full Title: A single arm open label study to assess the efficacy, safety and tolerability and of once-monthly administration of subcutaneous C.E.R.A. for the maintenance of haemoglobin levels in pre-dialysis p... | |||||||||||||
Medical condition: Chronic renal anemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
